Review article: the treatment of fatty liver disease associated with the metabolic syndrome

Marchesini, G.; Natale, S.; Manini, R.; Agostini, F.

doi:10.1111/j.1365-2036.2005.02593.x

Cited by 17 publications

(15 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NAFLD, which can be defined by alcohol consumption less than 20 g/d (excluding hepatitis B virus and hepatitis C virus infections) [29], has been reported to be closely related with subsequent metabolic diseases [30]. In the present population study, however, the association between HS and LDL particle size was not modified by alcohol consumption or NAFLD.…”

Section: Discussioncontrasting

confidence: 57%

Low-density lipoprotein particle size in hepatic steatosis and metabolic syndrome

Kim

et al. 2010

Diabetol Metab Syndr

View full text Add to dashboard Cite

BackgroundHepatic steatosis (HS), the most frequent liver disorder, was reported to be an independent predictor of cardiovascular disease. HS, if combined with the metabolic syndrome (MetS), might have a synergistic effect on low-density lipoprotein (LDL) particle size.MethodsCarotid intima-media thickness (IMT) and plaque formation, and HS were diagnosed ultrasonographically, and the MetS was diagnosed using the ATP III criteria in 274 healthy workers (mean age ± SD, 43.5 ± 7.1 yrs). LDL particle size was measured with density gradient ultracentrifugation, and subfractions were classified as large, buoyant LDL I (27.2~28.5 nm) and small, dense LDL III (24.2~25.5). All participants were grouped into three categories: control, subjects with HS alone and those with both HS and the MetS.ResultsThe subjects with HS alone were 84 (30.7%), whereas those with HS and the MetS were 46 (16.8%). LDL peak particle sizes showed significant negative correlations with carotid mean IMTs. LDL peak particle size and LDL I (%) decreased significantly in the HS, showing the lowest values in the subjects with both HS and the MetS, and their association was independent, even adjusted for potential confounders. LDL III also showed independent associations across the groups.ConclusionHS alone was more prevalent than HS combined with the MetS in general population. For the patients with HS alone, LDL particle size and carotid atherosclerosis were found to fall in the middle of the control and those with both HS and the MetS.

show abstract

Section: Discussioncontrasting

confidence: 57%

Low-density lipoprotein particle size in hepatic steatosis and metabolic syndrome

Kim

et al. 2010

Diabetol Metab Syndr

View full text Add to dashboard Cite

show abstract

“…Finally, treatment of NAFLD with insulin-sensitizers approved for use in T2DM results in decreased liver enzymes and volume and improved hepatic histology [144][145][146] indicating a close pathogenetic relationship between T2DM and NAFLD, which is further supported by mitochondrial abnormalities [147,148] and (micro) circulatory changes shared by both conditions [125,149].…”

Section: Insulinmentioning

confidence: 99%

‘Endocrine NAFLD’ a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis

Lonardo

Carani

Carulli

et al. 2006

Journal of Hepatology

121

100

View full text Add to dashboard Cite

“…There is a consensus that the key mechanism of hepatic steatosis is the insulin resistance [9]. This observation prompted to investigate new drugs which may be useful in reducing the fatty content in the liver, the cornerstone in the treatment of NAFLD [10]. Although effective, dietary modifications and increased physical activity are associated with a low rate of compliance in the real life since recurrence is almost the rule [11,12].…”

Section: Introductionmentioning

confidence: 99%

Systematic review and meta-analysis on the adverse events of rimonabant treatment: Considerations for its potential use in hepatology

et al. 2009

View full text Add to dashboard Cite

BackgroundThe cannabinoid-1 receptor blockers have been proposed in the management of obesity and obesity-related liver diseases (fatty liver as NAFLD or NASH). Due to increasing number of patients to be potentially treated and the need to assess the advantage of this treatment in terms of risk/benefit, we analyze the side events reported during the treatment with rimonabant by a systematic review and meta-analysis of all randomized controlled studies.MethodsAll published randomized controlled trials using rimonabant versus placebo in adult subjects were retrieved. Relative risks (RR) with 95% confidence interval for relevant adverse events and number needed to harm was calculated.ResultsNine trials (n = 9635) were considered. Rimonabant 20 mg was associated with an increased risk of adverse event (RR 1.35; 95%CI 1.17-1.56), increased discontinuation rate (RR 1.79; 95%CI 1.35-2.38), psychiatric (RR 2.35; 95%CI 1.66-3.34), and nervous system adverse events (RR 2.35; 95%CI 1.49-3.70). The number needed to harm for psychiatric adverse events is 30.ConclusionRimonabant is associated with an increased risk of adverse events. Despite of an increasing interest for its use on fatty liver, the security profile and efficacy it is needs to be carefully assessed before its recommendation. At present the use of rimonabant on fatty liver cannot be recommended.

show abstract

Review article: the treatment of fatty liver disease associated with the metabolic syndrome

Cited by 17 publications

References 16 publications

Low-density lipoprotein particle size in hepatic steatosis and metabolic syndrome

Low-density lipoprotein particle size in hepatic steatosis and metabolic syndrome

‘Endocrine NAFLD’ a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis

Systematic review and meta-analysis on the adverse events of rimonabant treatment: Considerations for its potential use in hepatology

Contact Info

Product

Resources

About